Shukra Pharmaceuticals Q1 Results Revenue Drops Significantly to ₹317.80 Lakhs, Net Profit Decreases to ₹48.53 Lakhs

Shukra Pharmaceuticals Q1 Results 2024-2025: Shukra Pharmaceuticals released their Q1 results for the fiscal year 2024-2025 on August 12, 2024. The company reported revenue from operations of ₹317.80 lakhs for the quarter ended June 30, 2024, marking a 71.76% decrease compared to ₹1,088.39 lakhs in the previous quarter.

YOY, this represents a 71.71% decline from the ₹1,126.92 lakhs reported for Q1 of the previous fiscal year. This significant decrease reflects the ongoing challenges in the pharmaceutical sector and the impact of shifting market dynamics.

On a positive note, Shukra Pharmaceuticals managed to achieve a net profit of ₹48.53 lakhs for the quarter, contrasting sharply with the ₹398.59 lakhs net profit in the previous quarter, an 87.8% quarter-over-quarter drop.

YOY, the company experienced a substantial 87.8% reduction from the ₹398.59 lakhs reported in Q1 of the previous fiscal year. Despite these challenges, the company's efforts to manage costs and streamline operations have resulted in a stable financial position relative to the broader industry downturn.

For More Q1 results check our Twitter Page.

Shukra Pharmaceuticals Q1 Results 2024-2025

Here is a table of Shukra Pharmaceuticals's Q1 results for the fiscal year 2024-2025:

Source: Click Here

Shukra Pharmaceuticals Current Market Overview

Shukra Pharmaceuticals is currently valued at ₹286 crore in the market, with its shares trading at ₹65.3 each. The stock has seen a high of ₹130 and a low of ₹20.4 in the past year. It has a price-to-earnings ratio of 15.3, indicating how much investors are willing to pay for each unit of earnings.

The company's book value stands at ₹13.2 per share, and it offers a dividend yield of 0.18%. Shukra Pharmaceuticals boasts strong profitability metrics, with a return on capital employed (ROCE) of 44.2% and a return on equity (ROE) of 44.7%, reflecting good financial health and effective use of its resources.

Q1 Results

Here are Shukra Pharmaceuticals's financial results for Q4 FY 2023-2024 and Q1 FY 2024-2025:

About Shukra Pharmaceuticals

Shukra Pharmaceuticals is a company that makes and sells pharmaceutical products, including tablets, capsules, and injectable medicines. Established in 1993, it operates with a focus on manufacturing high-quality drugs and conducting laboratory testing.

The company is certified by WHO-GMP, which ensures that its products meet international standards for good manufacturing practices. Shukra Pharmaceuticals also helps other pharmaceutical companies by developing and producing various drugs and dosage forms.

Visit our website for more Q1 results.